论文部分内容阅读
目的分析左炔诺孕酮宫内节育系统(曼月乐)联合去氧孕烯炔雌醇片(妈富隆)在子宫腺肌症药物治疗中的疗效。方法 75例子宫腺肌症患者(已婚已育不愿手术),按照人院治疗的时间随机分为A、B、C组,各25例。A组给予单独应用曼月乐治疗,B组单独应用妈富隆药物治疗,C组给予曼月乐联合妈富隆治疗,对比三组女性患者治疗的效果。结果 C组治疗后痛经评分、子宫体积、子宫内膜厚度及血清CA125水平明显优于A组和B组,差异有统计学意义(P<0.05)。C组治疗总有效率高达96.00%,明显高于A组的76.00%和B组的72.00%,差异有统计学意义(P<0.05)。C组阴道出血发生率4.00%与A组的16.00%和B组的8.00%比较差异无统计学意义(P<0.05);C组脱环发生率为0与A组的8.00%和B组的比较差异无统计学意义(P>0.05)。结论曼月乐联合妈富隆在治疗子宫腺肌症具有起效快、安全性高、不影响妊娠、无创伤、并发症少等众多的优点,故该种治疗方法值得临床推广及借鉴。
Objective To analyze the curative effect of levonorgestrel intrauterine system (Mirena) and deoxygestrel ethinyl estradiol tablets (Marvelon) in the treatment of adenomyosis. Methods 75 patients with adenomyosis (married unwilling to surgery), according to the time of hospital treatment were randomly divided into A, B, C group, 25 cases each. Group A was treated with Mirena alone, Group B was treated with Marvelon alone, Group C was treated with Mirena together with Marvelon to compare the efficacy of the three groups of female patients. Results After treatment, the score of dysmenorrhea, the volume of uterus, the thickness of endometrium and the level of serum CA125 in group C were significantly better than those in group A and group B (P <0.05). The total effective rate in group C was as high as 96.00%, significantly higher than 76.00% in group A and 72.00% in group B, the difference was statistically significant (P <0.05). The incidence of vaginal bleeding was 4.00% in group C compared with 16.00% in group A and 8.00% in group B (P <0.05). The incidences of de-circulation in group C were 0 and 8.00% in group A and 8.00% in group B The difference was not statistically significant (P> 0.05). Conclusion Mirena combined with Marvelon treatment of adenomyosis has the advantages of fast onset, high safety, does not affect the pregnancy, no trauma, fewer complications and so on many advantages, so the treatment is worthy of clinical promotion and reference.